Core Viewpoint - Novo Nordisk is undergoing significant internal restructuring in response to underwhelming performance, with changes in leadership and organizational adjustments aimed at strengthening its market position in diabetes and obesity treatments [2][3][6]. Group 1: Internal Adjustments - The recent extraordinary general meeting resulted in the departure of seven board members, including the former chairman Helge Lund, with Lars Rebien Sørensen appointed as the new chairman [2][6]. - Novo Nordisk's strategic adjustments in China include the integration of its obesity and diabetes divisions to enhance the synergy of its semaglutide product line and solidify its leadership in the insulin market [3][11][13]. - The company plans to implement a major restructuring of its Chinese operations starting January 1, 2026, focusing on innovative insulin products and reinforcing the core position of GLP-1 drugs [13][14]. Group 2: Competitive Landscape - Novo Nordisk's net sales for the first three quarters reached 229.92 billion Danish Krone (approximately $35.7 billion), with a 15% year-on-year growth, driven by its core semaglutide products [14]. - The competition in the obesity treatment market is intensifying, with Pfizer acquiring Metsera for $10 billion, highlighting the aggressive strategies of major pharmaceutical companies in this sector [3][15][16]. - AstraZeneca has also entered the weight management market, focusing on next-generation treatments that preserve lean muscle mass, further complicating the competitive landscape for Novo Nordisk [4][16]. Group 3: Future Outlook - The narrowing sales gap between Novo Nordisk's semaglutide and Eli Lilly's tirzepatide indicates increasing competitive pressure, with only about $1.5 billion separating the two products [3][14]. - Novo Nordisk has agreed to lower obesity drug prices starting in 2026 to enhance accessibility, which may negatively impact its sales growth by a low single-digit percentage [17][18].